Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition
Yuanwang Pan, Han Han, Hai Hu, et al.
Cancer Cell (2022) Vol. 41, Iss. 1, pp. 88-105.e8
Open Access | Times Cited: 48

Showing 1-25 of 48 citing articles:

Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets
Shaosen Zhang, Xinyi Xiao, Yonglin Yi, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 55
SHP2: A Pleiotropic Target at the Interface of Cancer and Its Microenvironment
Nicole M. Sodir, Gaurav Pathria, Joanne I. Adamkewicz, et al.
Cancer Discovery (2023) Vol. 13, Iss. 11, pp. 2339-2355
Open Access | Times Cited: 43
Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy
Suman Mukhopadhyay, Hsin‐Yi Huang, Ziyan Lin, et al.
Cancer Research (2023) Vol. 83, Iss. 24, pp. 4095-4111
Open Access | Times Cited: 43
Patient‐derived xenograft model in cancer: establishment and applications
Ao Gu, Jiatong Li, Mengyao Li, et al.
MedComm (2025) Vol. 6, Iss. 2
Open Access | Times Cited: 5
KMT2 Family of H3K4 Methyltransferases: Enzymatic Activity-dependent and -independent Functions
Hieu T. Van, Guojia Xie, Peng Dong, et al.
Journal of Molecular Biology (2024) Vol. 436, Iss. 7, pp. 168453-168453
Open Access | Times Cited: 11
Sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-stage small cell lung cancer: a phase II clinical trial
Xiao Han, Jun Guo, Lingyu Li, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 8
Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions
Yibei Wang, Mohammed Safi, Fred R. Hirsch, et al.
Nature Reviews Clinical Oncology (2025) Vol. 22, Iss. 3, pp. 200-214
Closed Access | Times Cited: 1
Squamous cell cancers of the aero-upper digestive tract: A unified perspective on biology, genetics, and therapy
Brian S. Henick, Alison Taylor, Hiroshi Nakagawa, et al.
Cancer Cell (2025) Vol. 43, Iss. 2, pp. 178-194
Closed Access | Times Cited: 1
Proteogenomic characterization reveals tumorigenesis and progression of lung cancer manifested as subsolid nodules
Hang Su, Lixia Chen, Jun Wu, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
Metabolism pathway-based subtyping in endometrial cancer: An integrated study by multi-omics analysis and machine learning algorithms
Xiaodie Liu, Wenhui Wang, Xiaolei Zhang, et al.
Molecular Therapy — Nucleic Acids (2024) Vol. 35, Iss. 2, pp. 102155-102155
Open Access | Times Cited: 6
TNFR1 and TNFR2, Which Link NF-κB Activation, Drive Lung Cancer Progression, Cell Dedifferentiation, and Metastasis
Gongping Shi, Yinling Hu
Cancers (2023) Vol. 15, Iss. 17, pp. 4299-4299
Open Access | Times Cited: 13
Methylation of the chromatin modifier KMT2D by SMYD2 contributes to therapeutic response in hormone-dependent breast cancer
Ryan Blawski, Bujamin Vokshi, Xinyu Guo, et al.
Cell Reports (2024) Vol. 43, Iss. 5, pp. 114174-114174
Open Access | Times Cited: 5
Differences between lung adenocarcinoma and lung squamous cell carcinoma: Driver genes, therapeutic targets, and clinical efficacy
Yue Shen, Jie-Qi Chen, Xiangping Li
Genes & Diseases (2024) Vol. 12, Iss. 3, pp. 101374-101374
Open Access | Times Cited: 4
Multi-omic Sequencing of Intermediate to High-Risk Cutaneous Squamous Cell Carcinoma Identifies Critical Genes and Expression Patterns Associated with Disease and Poor Outcomes
Shams Nassir, Miranda Yousif, Xing Li, et al.
Journal of Investigative Dermatology (2025)
Closed Access
Advancing the genetic engineering toolbox by combining AsCas12a knock-in mice with ultra-compact screening
Wei Jin, Yexuan Deng, John E. La Marca, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Identifying KDM5B as the synthetic lethal target of KMT2D-mutated osteosarcoma
Liyu Yang, Jing Zhang, Yiting Jiang, et al.
Chemico-Biological Interactions (2025) Vol. 412, pp. 111451-111451
Closed Access
3D tumor cultures for drug resistance and screening development in clinical applications
Zheng Peng, Xiaolan Lv, Hao Sun, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access
A human model to deconvolve genotype-phenotype causations in lung squamous cell carcinoma
Julia Ogden, Robert M. Sellers, Sudhakar Sahoo, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Bridging the gap: how patient-derived lung cancer organoids are transforming personalized medicine
Chao‐Xing Liu, Chao Shi, Siya Wang, et al.
Frontiers in Cell and Developmental Biology (2025) Vol. 13
Open Access
Heterozygous Kmt2d loss diminishes enhancers to render medulloblastoma cells vulnerable to combinatory inhibition of LSD1 and OXPHOS
Shilpa S. Dhar, Calena Brown, Ali A. Rizvi, et al.
Cell Reports (2025) Vol. 44, Iss. 5, pp. 115619-115619
Closed Access
KMT2C deficiency drives transdifferentiation of double-negative prostate cancer and confer resistance to AR-targeted therapy
Jiacheng Guo, Li Ni, Qiuli Liu, et al.
Cancer Cell (2025)
Closed Access
A role for pH dynamics regulating transcription factor DNA binding selectivity
Kyle P. Kisor, Diego Garrido Ruiz, Matthew P. Jacobson, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 3
Landscape of targeted therapies for lung squamous cell carcinoma
Qiuxuan Chen, Xiao-Shuo Zheng, Weiting Cheng, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 3
“PRRX1-rearranged mesenchymal tumors”: expanding the immunohistochemical profile and molecular spectrum of a recently described entity with the proposed revision of nomenclature
Laura M. Warmke, Michael Michal, Petr Martínek, et al.
Virchows Archiv (2023) Vol. 483, Iss. 2, pp. 207-214
Closed Access | Times Cited: 8
Clinical significance of miR-9-5p in NSCLC and its relationship with smoking
Tianxiang Zhang, Xinchun Duan, Yong Cui, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top